Principal Investigator: Dr. Ben deBoisblanc
Louisiana State University Health Sciences Center Department
of Medicine, Section of Pulmonary/Critical Care Medicine
is currently conducting 2 clinical trials for the management
of Pulmonary Hypertension.
For information on any of our clinical trials, please contact
our clinical research coordinators at (504)-412-1676.
A Multi-National, Multi-Center, Randomized, double-Blind, Placebo-Controlled,
Parallel Group Study to Assess the Safety and Efficacy of
a Subject Optimized Dose of Sildenafil (20, 40, or 80 mg
Sildenafil TID) based on Toleration, when used in combination
with intravenous prostacyclin (epoprostenol) in the treatment
of pulmonary arterial hypertension.
This clinical research trial is to determine the safety and
effectiveness of sildenafil (Viagra®) as an add on therapy
in treating symptoms of pulmonary arterial hypertension in
patients who are currently on intravenous Flolan®.
To be included in this study you must:
- Have Pulmonary Arterial Hypertension
- Have been and are currently being treated with continuous
intravenous prostacyclin (Flolan®) for the
past 3 months
- Have not previously used sildenafil as an adjunctive
therapy for pulmonary hypertension
If you would like more information regarding this trial, please
contact Paula Lauto, RN at 504-412-1676
A long-term, open-label study to evaluate the safety of Sitaxentan
Sodium Treatment in patients with Pulmonary Arterial
Hypertension
This is a clinical research study designed to evaluate an investigational
medication for the treatment of pulmonary arterial hypertension.
To be included in this clinical trial you must:
- Have symptomatic pulmonary arterial hypertension (not
caused by thromboembolism or blood clots to the lung)
- Not have obstructive sleep apnea
- Not have liver or kidney disease
If you would like more information regarding this trial,
please contact Chris Glynn, RN at 504-412-1676
|
